Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

A method for ameliorating a symptom in a subject wherein the subject has a disorder selected from:

• spinocerebellar ataxia (SCA) associated with a polyglutamine repeat mutation, spinal and bulbar muscular atrophy (SBMA), dentatomral-pailidoluyssan atrophy (DRPLA), Pick's disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and frontotemporal dementia;
• wherein the method comprises parenterally administering to said subject a pharmaceutical formulation comprising trehalose as the sole active ingredient;
• wherein the concentration of trehalose in said formulation is between about 0.1% (w/v) to about 50% (w/v);
• and
• wherein the administration is completed within less than 120 minutes.